Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: VP of business development
Company: Akeso Biopharma Inc.
个人简介:
Dr. Michael Chen has dedicated himself to bio-pharmaceutical industry and global business development for years and has extensive experience and practical achievements in external innovation, pipeline cooperation and business development. Before joining Akeso, Dr. Chen worked as Head of External Innovation APAC for Merck KGaA. Dr. Chen led collaborations with local pharmaceutical/biotech companies, investor groups and academic institutions in China and APAC areas. Meanwhile, Dr. Chen was also responsible for the international business development department of Merck in China and APAC areas, carrying out a variety of internal and external business cooperation. Dr. Chen was also one of the leading members of Merck Asia and China research and development center, and one of the core members for expanding Merck’s oncology business and innovation collaboration in China.Dr. Chen received his bachelor’s degree of cell and molecular biology from University of Essex, a master’s degree in cancer immunotherapy from University of Nottingham and a Ph.D. degree in biochemistry from Imperial College London.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: CEO
Company: Convalife (Shanghai) Co., Ltd.
个人简介:
Dr. Shen Xiaokun, CEO of Convalife Pharmaceutical Co., Ltd., graduated from Wuhan University with degrees in clinical medicine and Bioscience, and obtained Ph.D degree in pharmacology from Shanghai Institute of Materia Medica, CAS. Dr. Shen has been engaged in the research and development of new drugs for small molecules and antibodies in Hengrui, Novartis and other well-known enterprises. Dr. Shen has more than 10 years of experience in the research and development of new drugs. He has led and participated ~10 projects in the clinical development of new drugs in the fields of anti-tumor, immunity, dermatology and other diseases. He has also helped several drugs to be successfully NDA in China, including first in class IL-17 antibody, Cosentyx, etc. Convalife originated from Latin “valere”, meaning “value and strong”Convalife is an innovative, research-based, clinical stage biopharmaceutical company focused on bringing innovative therapies for cancer, autoimmune and infectious diseases to patients in China and around the world. Convalife develops new therapies with the potential of 'first in class' and 'best in class', and has strong new drug R & D and clinical development capabilities. Convalife obtained investment of famous listed companies such as Wuxibiologics (HK. 02269), Menovo Pharmaceutical (603538) etc.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: Head, Johnson & Johnson Innovation, Asia Pacific
Company: Johnson & Johnson
个人简介:
Dan Wang MD is the Head of Johnson & Johnson Innovation in Asia Pacific, responsible for managing a portfolio of co-investments spanning across all three business sectors and expanding external networks within the innovation ecosystem. Dan has over 20 years’ experience in the life sciences sector. Prior to joining Johnson & Johnson Innovation, Dan worked with Becton Dickinson (BD), e-Capital Corporation, Express Scripts and Johnson & Johnson by leading the local and global Research & Development, Medical Affairs and clinical research teams. Dan has a strong track record in strategic innovation, identifying new product opportunities and external partnerships. Dan holds MD and MSc degrees from Peking University as well as an MBA from Goizueta Business School, and an MPH from Rollins School of Public Health at Emory University, Atlanta.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: CEO
Company: AccuGen Group
个人简介:
Dr. Jimmy Zhang has 20+ years of experience and expertise in both large pharmas and start-up companies, in strategy, management, business development, and operations, as well as in venture investments.  Jimmy is founder, chairman and CEO of AccuGen Group, focusing on gene and cell therapy.  He was a Venture Partner at Lilly Asia Ventures (LAV), and Vice President of Transactions at Johnson & Johnson, where he led the transactional and partnership management activities and strategy in Asia Pacific region in pharmaceuticals, medical devices & diagnostics and consumer products, as well as fund relationship and partnership.  Jimmy was the Managing Director, MSD Early Investments – Greater China at Merck & Co., and a member of Merck Research Lab (China) Senior Leadership Team.  He was also a Board Director of BeiGene (Beijing) Co, Ltd. and an Advisor Board member of Cenova Ventures.  Jimmy was previously SVP at Synergenics (an accelerator founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry), a consultant at McKinsey & Company, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis). Jimmy was a founding member and former Chairman of BayHelix Group.  He is an adjunct professor and master degree mentor at Yeehong Business School at Shenyang Pharmaceutical University.  He holds an MBA from MIT Sloan School of Management, where he was elected as the treasurer of MIT Graduate Student Council; a PhD in biomedical sciences from University of Texas Southwestern Medical Center at Dallas, where he worked closely with three Nobel Laureates; and a BS in biochemistry from Nanjing University.  Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents.